[Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].

Date publication

mars 2017

Journal

Gynecologie, obstetrique, fertilite & senologie

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FROCHOT Céline

Tous les auteurs :
Azaïs H, Frochot C, Grabarz A, Khodja Bach S, Colombeau L, Delhem N, Mordon S, Collinet P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28359805

Résumé

Epithelial ovarian cancer (EOC) management remains association of debulking surgery in combination with platinum-based chemotherapy. Sixty percent of women with EOC considered in remission will develop recurrent disease. An option to improve the completion of cytoreductive surgery may be the use of photodynamic therapy to induce necrosis of peritoneal metastases. A limit of this technique was the toxicity induced by the lack of specificity of old-generation photosensitizer (PS) for tumor tissue if the light could not be specifically applied. To solve this problem, a solution is the design of selective PS. Folate receptor is a promising target for EOC targeted therapy. We present preclinical results concerning properties of a folic-acid targeted photosensitizer.

Mots clés

Cancer de l’ovaire, Fluorescence, Folate receptor, Ovarian cancer, Photodynamic therapy, Photosensibilisateur, Photosensitizer, Récepteur au folate, Thérapie photodynamique

Référence

Gynecol Obstet Fertil Senol. 2017 Mar;: